Sean McCarthy
Chief Executive Officer CytomX Therapeutics
Sean McCarthy is Chairman and CEO CytomX. A cancer researcher by training, he has led the company for fifteen years through its early days as a private, venture-backed company to the public market. Under Sean’s leadership, CytomX has pioneered the field of antibody masking with its Probody® Therapeutic platform. Sean has more than thirty years of experience in the biotechnology industry encompassing roles in R&D management, BD and venture capital. He received a B.Sc. in biochemistry and pharmacology from King’s College London, an MBA from the Rady School of Management at UCSD, and a D.Phil. from the University of Oxford.
Seminars
Wednesday 25th February 2026
CX-2051: Unlocking EpCAM as a Cancer Target via a Masked EPCAM-Directed Topo1 ADC
5:00 pm
- EpCAM is highly and uniformly expressed in CRC, but its normal tissue expression has precluded targeting EpCAM with systemic therapies
- Introducing CX-2051 as a first-in-class masked EpCAM targeted Topo1 ADC with compelling preclinical profile and early Phase I data
- CX-2051 is being rapidly advanced in the clinic in CRC with a path to expanding to other EpCAM expressing solid tumours
